Precigen, Inc. (PGEN)
NASDAQ: PGEN · Real-Time Price · USD
1.435
-0.155 (-9.75%)
Mar 31, 2025, 1:11 PM EDT - Market open

Company Description

Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.

It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.

It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors.

In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV+ solid tumors; PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis; and AG019, which is in Phase 1b/2a trial, to treat type 1 diabetes mellitus.

Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications.

The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020.

Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

Precigen, Inc.
Precigen logo
Country United States
Founded 1998
Industry Biotechnology
Sector Healthcare
Employees 143
CEO Helen Sabzevari

Contact Details

Address:
20374 Seneca Meadows Parkway
Germantown, Maryland 20876
United States
Phone 301 556 9900
Website precigen.com

Stock Details

Ticker Symbol PGEN
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001356090
CUSIP Number 74017N105
ISIN Number US74017N1054
SIC Code 2834

Key Executives

Name Position
Dr. Helen Sabzevari MPH, Ph.D. President, Chief Executive Officer and Director
Randal J. Kirk J.D. Executive Chairman
Harry Thomasian Jr. Chief Financial Officer
Rutul R. Shah Chief Operating Officer
Donald P. Lehr J.D., Ph.D. Chief Legal Officer and Corporate Secretary
Steven Harasym Vice President and Head of Investor Relations
Rob Russell Vice President and Head of Human Resources
Dr. Douglas E. Brough Ph.D. Senior Vice President and Head of Research
Dr. Bryan T. Butman Ph.D. Senior Vice President and Head of CMC
Dr. Amy R. Lankford Ph.D. Senior Vice President and Head of Clinical Operations and Regulatory Affairs

Latest SEC Filings

Date Type Title
Mar 19, 2025 10-K Annual Report
Mar 19, 2025 8-K Current Report
Feb 12, 2025 SCHEDULE 13G/A Filing
Jan 16, 2025 8-K Current Report
Dec 30, 2024 SCHEDULE 13D/A Filing
Dec 30, 2024 8-K Current Report
Dec 26, 2024 8-K Current Report
Nov 14, 2024 10-Q Quarterly Report
Nov 14, 2024 8-K Current Report
Nov 7, 2024 8-K Current Report